Praxis Precision Medicines
PRAX
92 hedge funds and large institutions have $792M invested in Praxis Precision Medicines in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
15% more funds holding
Funds holding: 80 → 92 (+12)
5% more capital invested
Capital invested by funds: $751M → $792M (+$40.8M)
0.09% more ownership
Funds ownership: 6.29% → 6.38% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.9M |
| 2 |
BlackRock
New York
|
+$11.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.33M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$5.44M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$11.9M |
| 2 |
Blackstone Inc
New York
|
-$8.33M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.98M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.83M |
| 5 |
Morgan Stanley
New York
|
-$1.55M |
PRAX Hedge Fund Activity: Q3 2021 in Review
92 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2021, worth a combined $792M — up 5.4% from $751M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PRAX positions and 9 closed out — a net gain of 12 holders — while 38 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was Novo Holdings A/S, cutting an estimated $11.9M.
- 92 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2021, up from 80 in Q2 2021.
- Funds reported $792M of Praxis Precision Medicines stock for Q3 2021, up 5.4% quarter-over-quarter.
- 21 funds opened new Praxis Precision Medicines positions in Q3 2021 and 9 closed out, a net change of +12 holders.
- The largest Praxis Precision Medicines buyer in Q3 2021 was Vanguard Group, an estimated $11.9M added.
- The largest Praxis Precision Medicines seller in Q3 2021 was Novo Holdings A/S, an estimated $11.9M sold.
Based on aggregated 13F filings for Q3 2021.